Repros Therapeutics Inc. (RPRX) reported second quarter 2014 loss of 38 cents per share, in line with the year-ago loss but a penny wider than the Zacks Consensus Estimate of a loss of 37 cents.
The company’s revenues for the second quarter of 2014 were $2,000 as compared to $1,000 in the year-ago period, reflecting higher interest income as a result of a higher cash balance.
Quarter in Details
Both general and administrative (G&A) expenses and research and development (R&D) expenses were up during the reported quarter. While G&A expenses increased 7% to $1.3 million, R&D expenses were up 23% year over year to $7.5 million. G&A expenses increased primarily due to an increase in non-cash stock based compensation. R&D expenses were up due to increased investment in pipeline.
Androxal, the most advanced pipeline candidate at Repros, is being evaluated for the treatment of secondary hypogonadism. Repros is conducting two identical, 17-week, double-blind studies. These studies (ZA-305 and ZA-304) will compare the safety and efficacy of Androxal with a testosterone replacement therapy (topical gel) and placebo.
Repros expects to submit a new drug application (NDA) to the FDA for Androxal for the secondary hypogonadism indication by the end of this year.
Proellex is another candidate in Repros’ pipeline. Proellex is being developed for several indications including uterine fibroids and severe endometriosis.
Repros currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Endo International (ENDP), Salix Pharmaceuticals (SLXP) and Anacor Pharmaceuticals, Inc. (ANAC). While Endo carries a Zacks Rank #1 (Strong Buy), Salix Pharma and Anacor Pharma are Zacks Rank #2 (Buy) stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment